Pet Pharm Biotech Co., Ltd. (TPEX:7762)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Western Medicine and Class B Patent Medicines	222.03M	130.70M	117.87M
Western Medicine and Class B Patent Medicines Growth	69.88%	10.89%	-
Total	222.03M	130.70M	117.87M
Total Growth	69.88%	10.89%	-

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Taiwan	222.03M	130.70M	117.87M
Taiwan Growth	69.88%	10.89%	-
Total	222.03M	130.70M	117.87M
Total Growth	69.88%	10.89%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 19, 2026

Data Sources Report a data error